CLL-495 Treatment Characteristics and Outcomes of Patients With Chronic/Small Lymphocytic Leukemia (CLL) Treated With Venetoclax and Bruton Tyrosine Kinase Inhibitor (BTKi) Combination Therapies
Year: 2024
Type: conference-abstract
Authors: Hande H. Tuncer, Nilanjan Ghosh, Isabelle Fleury, Lori A. Leslie, Beenish S. Manzoor, Nicole Lamanna, Toby A. Eyre, Brian T. Hill, Jennifer R. Brown, Wendy Sinai, Catherine C. Coombs, Chaitra Ujjani, Lindsey E. Roeker, Nnadozie Emechebe, Paul M. Barr, Matthew S. Davids, Nicolas Martinez-Calle, Joanna M. Rhodes, Frederick Lansigan, Laurie Pearson, Yun Choi, Stephen J. Schuster, Alan P. Skarbnik, Bita Fakhri, Michael Coyle, Deborah M. Stephens, Meghan C. Thompson, Christopher E. Jensen, Steven E. Marx, Dureshahwar Jawaid, Anna Schuh, Irina Pivneva, Talissa Watson, Annie Guerin, Mazyar Shadman
Institutions: Dana-Farber Cancer Institute, Levine Cancer Institute, Hôpital Maisonneuve-Rosemont, Université de Montréal, Hackensack Meridian Health, AbbVie (United States), Columbia University, Churchill Hospital, University of Oxford, Cleveland Clinic, University of California, Irvine, Fred Hutch Cancer Center, Memorial Sloan Kettering Cancer Center, University of Rochester Medicine, Nottingham University Hospitals NHS Trust, Rutgers Cancer Institute, Dartmouth–Hitchcock Medical Center, University of Massachusetts Chan Medical School, Tufts Medical Center, University of Pennsylvania, Novant Health, Stanford Cancer Institute, Stanford University, Lowell General Hospital, University of North Carolina at Chapel Hill, UNC Lineberger Comprehensive Cancer Center
Language: English
Subfield: Genetics (clinical)
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4401876713